Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011) |
OMB No. 0651-0050 (Exp 09/20/2020) |
Response to Office Action
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88639146 |
LAW OFFICE ASSIGNED |
LAW OFFICE 105 |
MARK SECTION |
MARK |
mark |
LITERAL ELEMENT |
REMIX |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
MARK STATEMENT |
The mark consists of standard characters, without claim to any particular font style, size or color. |
OWNER SECTION (current) |
NAME |
Remix Therapeutics Inc. |
MAILING ADDRESS |
400 Technology Square |
CITY |
Cambridge |
STATE |
Massachusetts |
ZIP/POSTAL CODE |
02139 |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
OWNER SECTION (proposed) |
NAME |
Remix Therapeutics Inc. |
MAILING ADDRESS |
400 Technology Square |
CITY |
Cambridge |
STATE |
Massachusetts |
ZIP/POSTAL CODE |
02139 |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
ARGUMENT(S) |
The Remarks and Amendments are attached herewith as a .PDF file to preserve the formatting of the text. |
EVIDENCE SECTION |
EVIDENCE FILE NAME(S) |
ORIGINAL PDF FILE |
evi_1-38111352-2020062311 4110195915_._R0826.20000U
S0_-_Response.pdf |
CONVERTED PDF FILE(S)
(4 pages) |
\\TICRS\EXPORT18\IMAGEOUT 18\886\391\88639146\xml1\ ROA0002.JPG |
|
\\TICRS\EXPORT18\IMAGEOUT 18\886\391\88639146\xml1\ ROA0003.JPG |
|
\\TICRS\EXPORT18\IMAGEOUT 18\886\391\88639146\xml1\ ROA0004.JPG |
|
\\TICRS\EXPORT18\IMAGEOUT 18\886\391\88639146\xml1\ ROA0005.JPG |
DESCRIPTION OF EVIDENCE FILE |
Remarks and Amendments |
GOODS AND/OR SERVICES SECTION (042) (current) |
INTERNATIONAL CLASS |
042 |
DESCRIPTION |
Pharmaceutical and therapeutic preparations; pharmaceutical, medical, scientific, and biopharmaceutical research and development |
FILING BASIS |
Section 1(b) |
GOODS AND/OR SERVICES SECTION (042) (proposed) |
INTERNATIONAL CLASS |
042 |
TRACKED TEXT DESCRIPTION |
Pharmaceutical and therapeutic preparations; pharmaceutical, medical,
scientific, and biopharmaceutical research and development |
FINAL DESCRIPTION |
pharmaceutical, medical, scientific, and biopharmaceutical research and development |
FILING BASIS |
Section 1(b) |
GOODS AND/OR SERVICES SECTION (005)(class added) |
INTERNATIONAL CLASS |
005 |
DESCRIPTION |
pharmaceutical and therapeutic preparations for the treatment of cancer, immune system related diseases and disorders, cardiovascular
diseases and disorders, genetic diseases and disorders, and neurological diseases and disorders |
FILING BASIS |
Section 1(b) |
CORRESPONDENCE INFORMATION (current) |
NAME |
CHRISTINA M. LICURSI, ESQ. |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
cxltrademarks@wolfgreenfield.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
NOT PROVIDED |
DOCKET/REFERENCE NUMBER |
R08262000000 |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
Christina M. Licursi, Esq. |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
cxltrademarks@wolfgreenfield.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
azstrademarks@wolfgreenfield.com |
DOCKET/REFERENCE NUMBER |
R08262000000 |
PAYMENT SECTION |
APPLICATION FOR REGISTRATION PER CLASS |
275 |
NUMBER OF CLASSES |
1 |
TOTAL FEES DUE |
275 |
SIGNATURE SECTION |
DECLARATION SIGNATURE |
I elect not to submit a signed declaration because I believe one is not required by the Trademark Rules of Practice. I understand that I still
may be required to submit a signed declaration. |
RESPONSE SIGNATURE |
/Amanda Slade/ |
SIGNATORY'S NAME |
Amanda Slade |
SIGNATORY'S POSITION |
Associate Attorney, Wolf, Greenfield & Sacks, P.C., Massachusetts Bar Member |
SIGNATORY'S PHONE NUMBER |
617-646-8193 |
DATE SIGNED |
06/23/2020 |
AUTHORIZED SIGNATORY |
YES |
FILING INFORMATION SECTION |
SUBMIT DATE |
Tue Jun 23 13:08:55 ET 2020 |
TEAS STAMP |
USPTO/ROA-XX.XXX.XX.X-202
00623130855469054-8863914
6-710514a49b4ac977d4e1eff
ac0d052a8ea011b922ef87925
76ec129dd97cb2d-CC-085303
08-20200623114110195915 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011) |
OMB No. 0651-0050 (Exp 09/20/2020) |
Response to Office Action
To the Commissioner for Trademarks:
Application serial no.
88639146 REMIX(Standard Characters, see http://uspto.report/TM/88639146/mark.png) has been amended as follows:
ARGUMENT(S)
In response to the substantive refusal(s), please note the following:
The Remarks and Amendments are attached herewith as a .PDF file to preserve the formatting of the text.
EVIDENCE
Evidence has been attached: Remarks and Amendments
Original PDF file:
evi_1-38111352-2020062311 4110195915_._R0826.20000U
S0_-_Response.pdf
Converted PDF file(s) ( 4 pages)
Evidence-1Evidence-2Evidence-3Evidence-4
CLASSIFICATION AND LISTING OF GOODS/SERVICES
Applicant proposes to amend the following:
Current:
Class 042 for Pharmaceutical and therapeutic preparations; pharmaceutical, medical, scientific, and biopharmaceutical research and development
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
Proposed:
Tracked Text Description: Pharmaceutical and therapeutic preparations;
pharmaceutical, medical, scientific, and biopharmaceutical
research and developmentClass 042 for pharmaceutical, medical, scientific, and biopharmaceutical research and development
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
Applicant hereby adds the following class of goods/services to the application:
New: Class 005 for pharmaceutical and therapeutic preparations for the treatment of cancer, immune system related diseases and disorders, cardiovascular diseases and disorders, genetic
diseases and disorders, and neurological diseases and disorders
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
OWNER AND/OR ENTITY INFORMATION
Applicant proposes to amend the following:
Current: Remix Therapeutics Inc., a corporation of Delaware, having an address of
400 Technology Square
Cambridge, Massachusetts 02139
United States
Proposed: Remix Therapeutics Inc., a corporation of Delaware, having an address of
400 Technology Square
Cambridge, Massachusetts 02139
United States
Email Address: XXXX
Correspondence Information (current):
CHRISTINA M. LICURSI, ESQ.
PRIMARY EMAIL FOR CORRESPONDENCE: cxltrademarks@wolfgreenfield.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED
The docket/reference number is R08262000000.
Correspondence Information (proposed):
Christina M. Licursi, Esq.
PRIMARY EMAIL FOR CORRESPONDENCE: cxltrademarks@wolfgreenfield.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): azstrademarks@wolfgreenfield.com
The docket/reference number is R08262000000.
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
FEE(S)
Fee(s) in the amount of $275 is being submitted.
SIGNATURE(S)
Declaration Signature
The filing Attorney has elected not to submit the signed declaration, believing no supporting declaration is required under the
Trademark Rules of Practice.
Response Signature
Signature: /Amanda Slade/ Date: 06/23/2020
Signatory's Name: Amanda Slade
Signatory's Position: Associate Attorney, Wolf, Greenfield & Sacks, P.C., Massachusetts Bar Member
Signatory's Phone Number: 617-646-8193
The signatory has confirmed that he/she is a U.S.-licensed attorney who is an active member in good standing of the bar of the highest court of a U.S. state (including the District of Columbia and
any U.S. Commonwealth or territory); and he/she is currently the owner's/holder's attorney or an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another
U.S.-licensed attorney not currently associated with his/her company/firm previously represented the owner/holder in this matter: the owner/holder has revoked their power of attorney by a signed
revocation or substitute power of attorney with the USPTO; the USPTO has granted that attorney's withdrawal request; the owner/holder has filed a power of attorney appointing him/her in this matter;
or the owner's/holder's appointed U.S.-licensed attorney has filed a power of attorney appointing him/her as an associate attorney in this matter.
Mailing Address: CHRISTINA M. LICURSI, ESQ.
WOLF GREENFIELD & SACKS, P.C.
600 ATLANTIC AVENUE
BOSTON, Massachusetts 02210
Mailing Address: Christina M. Licursi, Esq.
WOLF GREENFIELD & SACKS, P.C.
600 ATLANTIC AVENUE
BOSTON, Massachusetts 02210
RAM Sale Number: 88639146
RAM Accounting Date: 06/23/2020
Serial Number: 88639146
Internet Transmission Date: Tue Jun 23 13:08:55 ET 2020
TEAS Stamp: USPTO/ROA-XX.XXX.XX.X-202006231308554690
54-88639146-710514a49b4ac977d4e1effac0d0
52a8ea011b922ef8792576ec129dd97cb2d-CC-0
8530308-20200623114110195915